

CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:

202408Orig1s000

Trade Name: AVACLXR

Generic or Proper Name: acyclovir ophthalmic ointment

Sponsor: Fera Pharmaceuticals, LLC

Approval Date: March 29, 2019

Indication: treatment of acute herpetic keratitis (dendritic ulcers) in patients with herpes simplex (HSV-1 and HSV-2) virus

CENTER FOR DRUG EVALUATION AND RESEARCH

202408Orig1s000

CONTENTS

Reviews / Information Included in this NDA Review.

| | |
|------------------------------------------------------|----------|
| Approval Letter | X |
| Other Action Letters | X |
| Labeling | X |
| REMS | |
| Summary Review | X |
| Officer/Employee List | X |
| Office Director Memo | X |
| Cross Discipline Team Leader Review | |
| Clinical Review(s) | X |
| Product Quality Review(s) | X |
| Non-Clinical Review(s) | X |
| Statistical Review(s) | X |
| Clinical Microbiology / Virology Review(s) | X |
| Clinical Pharmacology Review(s) | X |
| Other Reviews | X |
| Risk Assessment and Risk Mitigation Review(s) | |
| Proprietary Name Review(s) | X |
| Administrative/Correspondence Document(s) | X |

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

202408Orig1s000

APPROVAL LETTER



NDA 202408

NDA APPROVAL

Fera Pharmaceuticals, LLC
Attention: John D' Angelo, M.S., R.Ph.
Vice President Regulatory Affairs
134 Birch Hill Road
Locust Valley, NY 11560

Dear Mr. D' Angelo:

Please refer to your New Drug Application (NDA) dated and received May 31, 2013, and your amendments, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Avaclyr (acyclovir ophthalmic ointment) 3%. This new drug application provides for the use of Avaclyr (acyclovir ophthalmic ointment) 3% for treatment of herpetic keratitis (dendritic ulcers).

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text. As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling text for the Prescribing Information as well as annual reportable changes not included in the enclosed labeling. Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*, available at <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>

The SPL will be accessible via publicly available labeling repositories.

CARTON AND CONTAINER LABELING

Submit final printed carton and container labeling that are identical to the enclosed carton and container labeling submitted on May 25, 2016, as soon as they are available, but no more than 30 days after they are printed. Please submit these labeling electronically according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (April 2018, Revision 5)*. For administrative purposes, designate this submission “**Final Printed Carton and Container Labeling for approved NDA 202408.**” Approval of this submission by FDA is not required before the labeling is used.

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, inapplicable or exempt. Because this drug product for this indication has an orphan drug designation, you are exempt from this requirement.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the Prescribing Information, Medication Guide, and Patient Package Insert (as applicable) to:

OPDP Regulatory Project Manager
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion
5901-B Ammendale Road
Beltsville, MD 20705-1266

Alternatively, you may submit a request for advisory comments electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft Guidance for Industry (available at: <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM443702.pdf>).

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the Prescribing Information, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. Form FDA 2253 is available at <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>. Information and Instructions for completing the form can be found at <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see <http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm>.

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Lois Almoza, M.S., Regulatory Health Project Manager, at 301-796-1600.

Sincerely,

{See appended electronic signature page}

Wiley A. Chambers, M.D.
Deputy Director
Division of Transplant and Ophthalmology Products
Office of New Drugs
Center for Drug Evaluation and Research

ENCLOSURES:

Content of Labeling
Carton and Container Labeling

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

WILEY A CHAMBERS
03/29/2019 11:09:55 AM